Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male and female~* Age of 50 years or older~* Permanent, paroxysmal, or persistent atrial fibrillation (at screening or within 6 months prior to enrollment) documented by 12-lead electrocardiogram)~* At least 1 of the following risk factors for stroke:~  * Prior stroke or transient ischemic attack~ * Age of 75 years or older~ * Arterial hypertension on treatment~ * Diabetes mellitus~ * Heart failure (New York Health Authority Class 2 or greater at time of enrollment)~ * Left ventricular ejection fraction of 35% or less, documented within 6 months of enrollment~ * Peripheral arterial disease (previous arterial revascularization, limb or foot amputation, or current intermittent claudication with ankle-arm systolic blood pressure ratio \<0.9)~* Not currently receiving vitamin K antagonist therapy for 1 of the following reasons:~  * Previous vitamin K antagonist therapy demonstrated as unsuitable and discontinued~ * Vitamin K antagonist therapy not previously used but expected unsuitable~Key Exclusion Criteria:~* Women who are pregnant or breast feeding~* Women of child bearing potential who are unwilling to meet the study requirements for pregnancy testing or are unwilling or unable to use an acceptable method to avoid pregnancy~* Atrial fibrillation due to reversible causes, such as thyrotoxicosis or pericarditis~* Valvular disease requiring surgery~* Planned ablation procedure for atrial fibrillation to be performed within 3 months~* Conditions other than atrial fibrillation that require chronic anticoagulation (such as, prosthetic mechanical heart valve, venous thromboembolism)~* Patients with serious bleeding in the last 6 months or at high risk for bleeding, including but not limited to those with:~  * Active peptic ulcer disease~ * Platelet count \<100,000/mm\^3 or hemoglobin \<10g/dL~ * Recent stroke (within 10 days)~ * Documented hemorrhagic tendencies or blood dyscrasias~* Current alcohol or drug abuse or psychosocial reasons that make study participation impractical~* Severe comorbid condition with life expectancy \<1 year~* Severe renal insufficiency; any patient with a serum creatinine level \>2.5 mg/dL or a calculated creatinine clearance \<25 mL/min is excluded~* Alanine transaminase or aspartate aminotransferase levels \>2 times upper limit of normal (ULN) or a total bilirubin level \>1.5 times ULN (unless an alternative causative factor \[such as Gilbert's syndrome\] is identified)~* Allergy or adverse reaction to acetylsalicylic acid~* Required treatment with a thienopyridine (clopidogrel or ticlopidine)~* Prisoners or participants who are compulsory detained (involuntarily incarcerated)~* Use of an investigational drug or device within the past 30 days or prior randomization into an apixaban clinical study~* Patients who are compulsorily detained for treatment for a psychiatric or physical illness

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: EXPERIMENTAL): None
- Acetylasalicylic acid (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).